Advertisement

Topics

Shire reports positive data from Phase III trial of Intuniv for ADHD

19:00 EDT 21 Sep 2017 | Net Resources International

Irish biotechnology firm Shire and its Japanese partner Shionogi have reported positive top-line results from a Phase III clinical trial of Intuniv (guanfacine hydrochloride prolonged release) in adults with attention deficit hyperactivity disorder (…

Original Article: Shire reports positive data from Phase III trial of Intuniv for ADHD

NEXT ARTICLE

More From BioPortfolio on "Shire reports positive data from Phase III trial of Intuniv for ADHD"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...